212Pb-DOTAMTATE showed significant antitumor activity in PRRT-exposed GEP-NET patients, with a 34.6% ORR and 96.2% disease control rate per investigator review. Investigator-assessed 18-month PFS and ...
Cizzle Bio Inc. founder and CEO Bill Behnke moderated a high-profile panel at the 2025 Association for Value-Based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback